FCM
BIIB icon

Fairbanks Capital Management’s Biogen BIIB Stock Holding History

Fairbanks Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,518
Closed -$430K – 51
2020
Q3 		$430K Hold
1,518
– – 0.43% 49
2020
Q2 		$438K Buy
+1,518
New +$456K 0.43% 49

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fairbanks Capital Management's BIIB Position: Q4 2020 in Review

Fairbanks Capital Management sold out of Biogen (BIIB) in Q4 2020, closing a stake of 1,518 shares — an estimated $430K sold.

Fairbanks Capital Management first reported a position in BIIB in Q2 2020 and held it in 2 quarters. The position peaked at $438K in Q2 2020. 1,060 funds tracked by Wall St. Rank hold BIIB as of Q4 2020.

  • Fairbanks Capital Management reported no remaining Biogen position as of Q4 2020 after selling out during the quarter.
  • Fairbanks Capital Management sold 1,518 Biogen shares in Q4 2020, an estimated $430K.
  • Fairbanks Capital Management first reported a position in Biogen in Q2 2020 and held it in 2 quarters.
  • Fairbanks Capital Management's Biogen position peaked at $438K in Q2 2020.
  • 1,060 funds tracked by Wall St. Rank held Biogen as of Q4 2020.

Based on Fairbanks Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.